News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-03-14 EDT			5-day change	1st Jan Change
111.44 ^USD	-0.99%		-5.08%	+20.65%

03-13	Nurix Therapeutics Appoints Roy D. Baynes to Its Board of Directors	CI
03-12	Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option	CI

Gilead Sciences - Women's History Month Celebrated With Its Team	03-14	AQ
Ex-dividend day	03-13	FA
Nurix Therapeutics Appoints Roy D. Baynes to Its Board of Directors	03-13	CI
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet	03-12	AQ
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option	03-12	BU
Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option	03-12	CI
Gilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study	03-11	MT
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet	03-11	BU
Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention	03-11	RE
Gilead Sciences, Inc. Presents the First Data from Its Ongoing Phase 1 Study Investigating Two Novel, Once-Yearly Formulations of Lenacapavir	03-11	CI
Gilead Sciences, Inc. Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 10:40 AM	03-11
Morgan Stanley Adjusts Price Target on Gilead Sciences to $130 From $123, Keeps Overweight Rating	03-11	MT
BofA Securities Adjusts Gilead Sciences Price Target to $126 From $116, Maintains Buy Rating	03-05	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $140 From $120, Keeps Overweight Rating	03-05	MT
Gilead Sciences, Inc. Presents at TD Cowen 45th Annual Healthcare Conference, Mar-04-2025 11:10 AM	03-04
Oppenheimer Adjusts Price Target on Gilead Sciences to $132 From $115, Keeps Outperform Rating	03-04	MT
Gilead Sciences sets aside $200 million to resolve HIV drug probe	03-03	RE
Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating	02-28	MT
Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU	02-24	MT
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention	02-24	BU
European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention	02-24	CI
Bernstein Adjusts Gilead Sciences Price Target to $120 From $105	02-21	MT
Gilead Sciences Gets Conditional Marketing Authorization for Liver Disease Treatment in European Economic Area	02-20	MT
Gilead's Seladelpar Granted Conditional European Marketing Authorization For The Treatment Of Primary Biliary Cholangitis	02-20	RE
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis	02-20	BU

5a0d09a6.5yHxzCj1OfRf5KIJzQL-pcCtJtGrSw0o_KXHTU0MhT4.kxa0ikmFZqIUycxHvi_H_LnpEOXCJllYhuSdGmBZ8gnKfsiWXI1wlW2s0Q

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Filters